Richard Francis

President and CEO, Teva Pharmaceutical Industries

About

Richard Francis is the President and Chief Executive Officer of Teva Pharmaceutical Industries, an Israeli-incorporated pharmaceutical company listed on the NYSE and the Tel Aviv Stock Exchange. Teva's 2026 proxy statement says he became President and CEO and joined the Board of Directors in January 2023. Teva's November 2026 results release to the SEC quotes him as President and CEO. The company describes itself as a biopharmaceutical business built on a generics business.

The proxy statement says Francis was CEO of Sandoz from 2014 to 2019 and a member of the Novartis executive team. Before that he spent 13 years at Biogen, where he held senior roles including leading its U.S. business. From 2021 to 2022 he was CEO of Purespring Therapeutics and of Forcefield Therapeutics. He holds a Bachelor of Arts in Economics from Manchester Metropolitan University. Other pharmaceutical company leaders on Whoo include Albert Bourla of Pfizer and Mike Doustdar of Novo Nordisk.

Whoo compiled this page from public sources: Teva 2026 proxy statement (SEC), Teva third-quarter 2026 results release (SEC), Teva Form 10-K (SEC). It is not affiliated with or endorsed by Richard Francis. Are you Richard Francis? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.

Want a page like this? Create yours from your résumé.

Experience

President, Chief Executive Officer and Director — Teva Pharmaceutical Industries


January 2023 – Present

Chief Executive Officer — Purespring Therapeutics and Forcefield Therapeutics


2021 – 2022

Chief Executive Officer — Sandoz


2014 – 2019

  • Member of the Novartis executive team
  • Senior Executive — Biogen


    13 years

  • Held several senior roles, including leading the U.S. business

Education

Bachelor of Arts in Economics — Manchester Metropolitan University


Projects